Monopar Therapeutics Inc Financials

MNPR

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

3/9

Monopar Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.41x

For every $1 of reported earnings, Monopar Therapeutics Inc generates $0.41 in operating cash flow (-$6.4M OCF vs -$15.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Monopar Therapeutics Inc (MNPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

Monopar Therapeutics Inc generated $0 in revenue in fiscal year 2024.

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$15.6M

YoY-85.5%

Monopar Therapeutics Inc reported -$15.6M in net income in fiscal year 2024. This represents a decrease of 85.5% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$45.8M

YoY+530.6%

5Y CAGR+28.2%

Monopar Therapeutics Inc held $45.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+104.7%

Monopar Therapeutics Inc had 6M shares outstanding in fiscal year 2024. This represents an increase of 104.7% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$13.0M

YoY+132.2%

5Y CAGR+45.9%

Monopar Therapeutics Inc invested $13.0M in research and development in fiscal year 2024. This represents an increase of 132.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

MNPR Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$0	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13.0M+132.2%	$5.6M-26.2%	$7.6M+16.9%	$6.5M+59.7%	$4.1M+106.5%	$2.0M
SG&A Expenses	$3.2M-2.3%	$3.2M+9.7%	$2.9M+11.8%	$2.6M+7.8%	$2.4M+3.8%	$2.4M
Operating Income	-$16.2M-83.0%	-$8.8M+16.2%	-$10.5M-15.4%	-$9.1M-40.2%	-$6.5M-50.5%	-$4.3M
Interest Expense	N/A	$429K+1920.1%	$21K-11.6%	$24K-70.7%	$82K-17.2%	$99K
Income Tax	$8000.0%	$8000.0%	$800	$0-100.0%	$18K	$0
Net Income	-$15.6M-85.5%	-$8.4M+20.1%	-$10.5M-15.5%	-$9.1M-44.4%	-$6.3M-49.2%	-$4.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M+163.1%	$984K	N/A	$1.3M	N/A	$1.7M	N/A	$1.8M
SG&A Expenses	$1.5M+154.5%	$591K	N/A	$749K	N/A	$675K	N/A	$632K
Operating Income	-$4.1M-159.9%	-$1.6M	N/A	-$2.1M	N/A	-$2.4M	N/A	-$2.5M
Interest Expense	N/A	$73K	N/A	$112K	N/A	$8K	N/A	$577
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.4M-163.6%	-$1.3M	N/A	-$2.0M	N/A	-$2.4M	N/A	-$2.5M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MNPR Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$60.3M+720.8%	$7.3M-44.5%	$13.2M-35.5%	$20.5M+21.7%	$16.9M+26.3%	$13.4M
Current Assets	$60.3M+722.2%	$7.3M-44.3%	$13.2M-35.8%	$20.5M+22.2%	$16.8M+27.0%	$13.2M
Cash & Equivalents	$45.8M+530.6%	$7.3M-11.2%	$8.2M-59.7%	$20.3M+21.3%	$16.7M+26.7%	$13.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.3M+199.0%	$1.8M-44.0%	$3.1M+98.5%	$1.6M+34.3%	$1.2M+62.5%	$724K
Current Liabilities	$5.3M+199.0%	$1.8M-43.8%	$3.1M+98.0%	$1.6M+34.3%	$1.2M+62.5%	$724K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$55.0M+885.0%	$5.6M-44.6%	$10.1M-46.7%	$18.9M+20.7%	$15.7M+24.3%	$12.6M
Retained Earnings	-$75.8M-25.9%	-$60.2M-16.2%	-$51.8M-25.5%	-$41.3M-28.3%	-$32.2M-24.4%	-$25.9M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$144.2M+139.2%	$60.3M+720.8%	$7.3M-14.5%	$8.6M-35.0%	$13.2M-8.4%	$14.4M-29.6%	$20.5M-8.9%	$22.5M
Current Assets	$144.1M+139.0%	$60.3M+722.2%	$7.3M-14.4%	$8.6M-34.9%	$13.2M-8.4%	$14.4M-30.0%	$20.5M-8.6%	$22.4M
Cash & Equivalents	$127.7M+178.7%	$45.8M+530.6%	$7.3M+31.7%	$5.5M-32.6%	$8.2M-42.8%	$14.3M-29.5%	$20.3M-9.1%	$22.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M-49.8%	$5.3M+199.0%	$1.8M-11.3%	$2.0M-36.8%	$3.1M+62.1%	$1.9M+22.4%	$1.6M+27.5%	$1.2M
Current Liabilities	$2.6M-51.1%	$5.3M+199.0%	$1.8M-11.3%	$2.0M-36.7%	$3.1M+63.4%	$1.9M+21.1%	$1.6M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$141.6M+157.2%	$55.0M+885.0%	$5.6M-15.5%	$6.6M-34.5%	$10.1M-19.3%	$12.5M-34.0%	$18.9M-11.0%	$21.3M
Retained Earnings	-$84.3M-11.2%	-$75.8M-25.9%	-$60.2M-3.1%	-$58.4M-12.7%	-$51.8M-5.9%	-$48.9M-18.5%	-$41.3M-6.9%	-$38.6M

MNPR Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$6.4M+18.5%	-$7.9M-8.7%	-$7.2M+1.2%	-$7.3M-56.9%	-$4.7M-54.5%	-$3.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$14.3M-391.0%	$4.9M+200.2%	-$4.9M	$0	N/A	N/A
Financing Cash Flow	$59.3M+2824.8%	$2.0M+6066.8%	$33K-99.7%	$10.9M+33.0%	$8.2M-12.5%	$9.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$2.1M-4.6%	-$2.0M-29.3%	-$1.5M+20.3%	-$1.9M-49.0%	-$1.3M+39.4%	-$2.1M-5.7%	-$2.0M-4.7%	-$1.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$2.1M+85.2%	-$14.3M-582.7%	$3.0M+22858.5%	-$13K+99.7%	-$4.9M	$0	N/A	N/A
Financing Cash Flow	$92.4M+64.6%	$56.1M+16679.9%	$335K+35.6%	$247K+77.8%	$139K+684.5%	-$24K-205.4%	-$8K+22.1%	-$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MNPR Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-25.9%+88.5pp	-114.4%-34.9pp	-79.5%-35.1pp	-44.4%-7.0pp	-37.4%-5.7pp	-31.6%
Current Ratio	11.47+7.3	4.17-0.0	4.21-8.8	12.98-1.3	14.28-4.0	18.27
Debt-to-Equity	0.10-0.2	0.310.0	0.31+0.2	0.080.0	0.07+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-2.4%+19.1pp	-21.5%	N/A	-22.7%	N/A	-16.6%	N/A	-10.9%
Current Ratio	56.10+44.6	11.47+7.3	4.17-0.2	4.32+0.1	4.21-3.3	7.51-5.5	12.98	N/A
Debt-to-Equity	0.02-0.1	0.10-0.2	0.31+0.0	0.30-0.0	0.31+0.2	0.15+0.1	0.08+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Foghorn Therapeutics Inc. FHTX

$325.1M

Lineage Cell The LCTX

$382.3M

Alector ALEC

$204.1M

Annexon, Inc. ANNX

$728.9M

Lexeo Therapeutics Inc LXEO

$460.6M

Frequently Asked Questions

What is Monopar Therapeutics Inc's annual revenue?

Monopar Therapeutics Inc (MNPR) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Monopar Therapeutics Inc profitable?

No, Monopar Therapeutics Inc (MNPR) reported a net income of -$15.6M in fiscal year 2024.

What is Monopar Therapeutics Inc's operating cash flow?

Monopar Therapeutics Inc (MNPR) generated -$6.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Monopar Therapeutics Inc's total assets?

Monopar Therapeutics Inc (MNPR) had $60.3M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Monopar Therapeutics Inc spend on research and development?

Monopar Therapeutics Inc (MNPR) invested $13.0M in research and development during fiscal year 2024.

How many shares does Monopar Therapeutics Inc have outstanding?

Monopar Therapeutics Inc (MNPR) had 6M shares outstanding as of fiscal year 2024.

What is Monopar Therapeutics Inc's current ratio?

Monopar Therapeutics Inc (MNPR) had a current ratio of 11.47 as of fiscal year 2024, which is generally considered healthy.

What is Monopar Therapeutics Inc's debt-to-equity ratio?

Monopar Therapeutics Inc (MNPR) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Monopar Therapeutics Inc's return on assets (ROA)?

Monopar Therapeutics Inc (MNPR) had a return on assets of -25.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Monopar Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Monopar Therapeutics Inc (MNPR) had $45.8M in cash against an annual operating cash burn of $6.4M. This gives an estimated cash runway of approximately 86 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Monopar Therapeutics Inc's Piotroski F-Score?

Monopar Therapeutics Inc (MNPR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Monopar Therapeutics Inc's earnings high quality?

Monopar Therapeutics Inc (MNPR) has an earnings quality ratio of 0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.